Developing the Right Tools to Inform Policy Decision Makers About the Clinical and Health Economic Consequences of Health Technologies

Modeling and Meta-Analysis (MMA) are powerful tools for making comprehensive assessments of the costs and benefits of healthcare interventions beyond clinical trials.

Why do we need modeling?

Health economic models provide vital information to inform allocation of available resources for maximizing health benefits. When payers make decisions about which technologies and/or services to fund, they assess the clinical and economic value of feasible alternatives by considering costs and outcomes over an appropriate time horizon for a range of patient subgroups. Clinical trials are designed for measurement and hypothesis testing, so they often fail to meet the requirements for decision-making.

What is a meta-analysis used for?

A meta-analysis is a type of evidence synthesis tool used for multiple studies to improve the precision and relevance of clinical and health outcomes data. A meta-analysis evaluation will help to organize, explain, and generate a single overall answer by using all available (and appropriate) information and also identifying any important trends or patterns for future research. The synthesized evidence can then be used to show the multiple components of a product’s value. These value components span across all of our Center of Excellence and can help inform nearly all of them.

A Customized Approach

  • Economic models to support reimbursement submissions around the world
  • Early models designed to inform commercial decision-making
  • Population-based dynamic transmission models
  • Global core models and country adaptations
  • Microsimulation of individual patient disease progression, treatment pathways, and outcomes
  • Simple calculators illustrating costs and outcomes
  • User-friendly graphical user interfaces
  • Nationally representative estimates of the budget impact to government payers
  • Models supporting economic value messages for AMCP dossiers
  • Graphical user interfaces and web-based applications for use in payer discussions
  • Systematic literature reviews and network meta-analyses to support economic modeling and HTA submissions
  • Clinical landscape and data comparability assessments
  • Indirect treatment comparisons of non-randomized data
  • Network meta-analysis and indirect treatment comparison of survival data
  • Meta-analysis of epidemiologic and other non-clinical data
  • Matching adjusted indirect comparisons
  • Simulated treatment comparisons
  • Survival analysis and extrapolation
  • Trial-based economic models

Why Us?

Our modeling experts are actively involved in the field.  We have the experience needed to guide you to the right solutions and be a partner in research.

0
Projects Delivered
0
HTA Submissions Supported Worldwide
0+
MMA Experts
0+
Cost-Effectiveness Models Delivered

Case Study

Resources

Meet Our Modeling and Meta-Analysis Team

Modeling and Meta-Analysis Publications

Physician Preferences for Non-Metastatic Castration-Resistant Prostate Cancer Treatment

Authors: S Srinivas, AF Mohamed, S Appukkuttan, M Botteman, X Ng, N Joshi, E Horodniceau, AR Waldeck, SJ Simmons

 Continue Reading

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer

Authors: D Goldstein, DD Von Hoff, EG Chiorean, M Reni, J Tabernero, RK Ramanathan, M Botteman, A Aly, S Margunato-Debay, B Lu, CU Louis, D McGovern, C Khoon Lee

 Continue Reading
Neurology

Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada

Authors: Marie-Claude Breton, Liping Huang, Sonya J. Snedecor, Noelle Cornelio, Fiorella Fanton-Aita

 Continue Reading

Please get in touch

To learn more about our Modeling and Meta-Analysis research and discuss what we could do for you, please get in touch.

Contact Us

Maarten Treur

Modeling and Meta-Analysis Lead

Email »